Physician profile
Mahnaz Momeni
NPI 1306924741
$14,647.85
in general payments reported to CMS, 2019-2025
40 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,653 · 2020: $799 · 2021: $1,056 · 2022: $1,340 · 2023: $2,592 · 2024: $3,370 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,463 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,462.65 |
| Education | $336.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,373.51 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $2,091.00 | 2019-2025 | |
| Amgen INC. | $1,784.86 | 2019-2025 | Tavneos, Otezla, Krystexxa |
| Ucb, INC. | $1,555.28 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,466.04 | 2019-2025 | |
| Horizon Therapeutics Plc | $561.46 | 2019-2023 | Krystexxa, Tepezza |
| Glaxosmithkline, LLC. | $549.15 | 2019-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $500.61 | 2023-2025 | Acthar |
| Lilly USA, LLC | $482.15 | 2019-2024 | Taltz |
| Pfizer INC. | $473.67 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $366.26 | 2019-2024 | Orencia |
| Celgene Corporation | $261.69 | 2019 | |
| Aurinia Pharma U.S., INC. | $259.34 | 2021-2025 | Lupkynis |
| Janssen Scientific Affairs, LLC | $200.06 | 2021-2022 | |
| Genentech USA, INC. | $187.07 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahnaz Momeni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.